ECC 2015: NETTER-1 trial showed rare cancer responded unusually well to new treatment

NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 1–2 metastatic midgut neuroendocrine tumours (NETs). The results to date showed 177Lu-DOTATATE provided a clinically meaningful and statistically significant increase in progression-free survival (PFS) in the patients treated with 177Lu-DOTATATE.

Presented at the European Cancer Conference (ECC) 2015 by Philippe Ruszniewski, MD, of Beaujon Hospital, Clichy, France

Year of Production:
Running Time:
Color/Sound:

2015
08:02
Color/Sound

Comments are closed.